Rsouth Antibodies

Rsouth Antibodies has developed a therapeutic antibody for Respiratory Syncytial Virus (RSV) that has been licensed to MedImmune (now AstraZeneca). AstraZeneca has finalized clinical validation and obtained regulatory approval for this antibody that is now marketed by Sanofi as Nirsevimab for prevention of RSV in infants. Since RSV infection have been on the rise again […]

Phlox Therapeutics

Phlox Therapeutics uses smart RNA designs to target multiple Lamin A/C mutations, offering therapies for rare genetic cardiomyopathies. Their constructs, developed by the group of Amsterdam UMC Professor Yigal Pinto, show promising therapeutic effects in patient-derived cardiomyocytes. Phlox Therapeutics aims to expand their technology to other treatment-resistant cardiomyopathies.

Parkinnova Therapeutics

Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.

PacingCure

PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.

Kling Biotherapeutics

Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.

GuanaRep

Repurposing the hypertension drug Guanabenz, GuanaRep aims to provide an affordable therapy for Vanishing White Matter, a rare neurological disease that mostly affects young children. Their research, led by Amsterdam UMC Professor Marjo van der Knaap, shows promising clinical results. GuanaRep focuses on making treatments accessible to patients worldwide.

Cellagenics

Developing STEP® technology, Cellagenics scales up therapeutic antibody production in mammalian cell lines. Their collaboration with Batavia Biosciences aims to enhance biopharmaceutical manufacturing.

AmbroSia Therapeutics

Harnessing glycan-modified antigens, AmbroSia Therapeutics aims to modulate immune responses. Their technology has potential applications in a wide variety of auto-immune diseases, oncology and infectious diseases. The initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.

Regenesance

Regenesance focuses on antibody engineering to treat neurodegenerative diseases and immune-mediated disorders. The company licenses its technology to Complement Pharma, aiming to develop therapies for conditions like ALS and multiple sclerosis. The company leverages groundbreaking research to improve patient outcomes.

AMI Pharma

AMI Pharma develops therapeutics compounds for Type 1 Diabetes and autoimmune diseases. Their research, based on IP from Amsterdam UMC and Wageningen University & Research, aims to bring new treatments to the clinical trials. AMI Pharma leverages extensive pre-clinical and clinical data to advance their therapeutic pipeline.